INO Investor Notice: Levi & Korsinsky Investigates Inovio Pharmaceuticals, Inc. for Securities Law Violations

Core Viewpoint - Inovio Pharmaceuticals is under investigation for potential violations of federal securities laws following the FDA's rejection of its accelerated approval request for INO-3107, leading to a significant drop in its stock price. Group 1: FDA Announcement - The FDA accepted Inovio's Biologics License Application (BLA) for INO-3107 for recurrent respiratory papillomatosis on a standard review timeline [2] - The FDA indicated that Inovio did not provide sufficient information to qualify for accelerated approval [2] - Inovio plans to request a meeting with the FDA to discuss pursuing accelerated approval despite the current standard review timeline [2] Group 2: Stock Market Reaction - Following the FDA announcement, Inovio's stock price fell over 24% on the same day [3] Group 3: Legal Investigation - Levi & Korsinsky has commenced an investigation into Inovio Pharmaceuticals regarding potential violations of federal securities laws [1] - The firm has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]